
Emergent BioSolutions is planning a major expansion of manufacturing capacity for its anthrax vaccine BioThrax to meet the biodefense objectives …

GlaxoSmithKline, Novartis and Emergent BioSolutions will share a $400 million contract from the US government to provide vaccine manufacturing capacity …

